scholarly journals The topical 5% lidocaine medicated plaster in localized neuropathic pain: a reappraisal of the clinical evidence

2016 ◽  
pp. 67 ◽  
Author(s):  
Oscar A de Leon-Casasola ◽  
Victor Mayoral Rojals
Keyword(s):  
Neuropathic Pain ◽  
Clinical Evidence ◽  
Localized Neuropathic Pain

scholarly journals The 5% Lidocaine-Medicated Plaster: Its Inclusion in International Treatment Guidelines for Treating Localized Neuropathic Pain, and Clinical Evidence Supporting its Use

2016 ◽  
Vol 5 (2) ◽  
pp. 149-169 ◽  
Author(s):  
Ralf Baron ◽  
Massimo Allegri ◽  
Gerardo Correa-Illanes ◽  
Guy Hans ◽  
Michael Serpell ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Clinical Evidence ◽  
Treatment Guidelines ◽  
Localized Neuropathic Pain

Use of capsaicin for the treatment of localized neuropathic pain post-thoracotomy

2021 ◽  
Author(s):  
José Anido ◽  
Elena Rojo ◽  
Iliana Funcia ◽  
Alejandra Becerra ◽  
Estella Bravo ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Localized Neuropathic Pain

scholarly journals Diabetic Peripheral Neuropathy: Epidemiology, Physiopathology, Diagnosis and Treatment

2019 ◽  
Vol 7 (1) ◽  
pp. 35-48
Author(s):  
Nazma Akter
Keyword(s):  
Neuropathic Pain ◽  
Peripheral Neuropathy ◽  
Diabetic Peripheral Neuropathy ◽  
Clinical Evidence ◽  
Current Treatment ◽  
Diabetic Patients ◽  
First Line ◽  
Diabetic Neuropathic Pain ◽  
Current Treatment Regimen ◽  
Limb Proprioception

Diabetic peripheral neuropathy (DPN) is a common complication of both type 1 and type 2 diabetes. It affects over 90% of the diabetic patients. It is widely accepted that the toxic effects of hyperglycemia play an important role in the development of this complication, but several other hypotheses have been postulated. It is typically characterized by significant deficits in tactile sensitivity, vibration sense, lower-limb proprioception, and kinesthesia. Painful DPN has been shown to be associated with significant reductions in overall quality of life, increased levels of anxiety and depression, sleep impairment, and greater gait variability. DPN is often misdiagnosed and inadequately treated. Clinical recognition of DPN is imperative for allowing timely symptom management to reduce the morbidity associated with this condition. The management of diabetic neuropathic pain consists basically in excluding other causes of painful peripheral neuropathy, improving glycemic control as a prophylactic therapy and using medications to alleviate pain. First line drugs for pain relief include anticonvulsants, such as pregabalin and gabapentin and antidepressants, especially those that act to inhibit the reuptake of serotonin and noradrenaline. In addition, there is experimental and clinical evidence that opioids can be helpful in pain control, mainly if associated with first line drugs. Other agents, including for topical application, such as capsaicin cream and lidocaine patches, have also been proposed to be useful as adjuvant in the control of diabetic neuropathic pain, but the clinical evidence is insufficient to support their use. The purpose of this review is to examine proposed mechanisms of DPN, summarize current treatment regimen. A better understanding of the mechanisms underlying diabetic neuropathic pain will contribute to the search of new therapies. Delta Med Col J. Jan 2019 7(1): 35-48

Effectiveness and safety of 5% lidocaine-medicated plaster on localized neuropathic pain after knee surgery

Pain ◽  
2019 ◽  
Vol 160 (5) ◽  
pp. 1186-1195 ◽  
Author(s):  
Gisèle Pickering ◽  
Marion Voute ◽  
Nicolas Macian ◽  
Hervé Ganry ◽  
Bruno Pereira
Keyword(s):  
Neuropathic Pain ◽  
Knee Surgery ◽  
Localized Neuropathic Pain

scholarly journals Localized neuropathic pain: an expert consensus on local treatments

2017 ◽  
Vol Volume 11 ◽  
pp. 2709-2718 ◽  
Author(s):  
Gisèle PICKERING ◽  
Elodie MARTIN ◽  
Florence Tiberghien ◽  
Claire Delorme ◽  
Gérard Mick
Keyword(s):  
Neuropathic Pain ◽  
Expert Consensus ◽  
Localized Neuropathic Pain
Sign in / Sign up

Export Citation Format

Share Document